p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.

There was a slightly higher proportion of carriers of pathogenic apolipoprotein E4 ( APOE4 ) alleles in the 400-mg group, although differences between groups did not reach statistical significance ( P = 0.09).

also in 111,027 other papers